The myeloid cell-surface glycoprotein CD13/ aminopeptidase N (APN; EC 3.4.11.2) contains a pentapeptide (HExxH) in its extracellular domain that is characteristic of many zincdependent metalloproteinases. This region contains residues important for zinc binding and constitutes part of the catalytic domain of several metalloproteases. We deleted an internal fragment of 117 base pairs (bp) from the human CD13/APN cDNA, resulting in an in-frame deletion that included the sequences coding for this pentapeptide motif. The mutant cDNA was subcloned into a retroviral expression vector, and polypeptides encoded by the altered cDNA were expressed in transfected murine NIH-3T3 fibroblasts. The mutant CD13/APN molecules lacked enzymatic activity, and HE CELL-SURFACE glycoprotein CD13 (also known T as gp150) was first identified on leukocytes of the myeloid series and was later shown to be identical to aminopeptidase N (APN; EC 3.4.11.2),1,2 a prominent membrane-bound metallopeptidase of epithelial cells that form the brush borders of the small intestine and renal tubules. CD13/APN exemplifies a group of cell-surface peptidases that have been found on discrete subsets of hematopoietic cells. While CD13/APN expression is restricted to myeloid progenitors and mature monocytes, macrophages, and granulocytes within the hematopoietic system, other membrane-bound peptidases show activity on granulocytes and lymphoid progenitors (CDlO/neutral endopeptidase; EC 3.4.24.11),3-5 activated T lymphocytes (CD26/dipeptidyl peptidase IV, EC 3.4.14.5),6-s and early B-lymphocyte progenitors (murine BP1/6C3, identical to aminopeptidase A, EC 3.4.11.7).9-"
T as gp150) was first identified on leukocytes of the myeloid series and was later shown to be identical to aminopeptidase N (APN; EC 3.4.11.2),1,2 a prominent membrane-bound metallopeptidase of epithelial cells that form the brush borders of the small intestine and renal tubules. CD13/APN exemplifies a group of cell-surface peptidases that have been found on discrete subsets of hematopoietic cells. While CD13/APN expression is restricted to myeloid progenitors and mature monocytes, macrophages, and granulocytes within the hematopoietic system, other membrane-bound peptidases show activity on granulocytes and lymphoid progenitors (CDlO/neutral endopeptidase; EC 3.4.24.11),3-5 activated T lymphocytes (CD26/dipeptidyl peptidase IV, EC 3.4.14.5),6-s and early B-lymphocyte progenitors (murine BP1/6C3, identical to aminopeptidase A, EC 3.4.11.7). 9-" We previously demonstrated that the APN activity of CD13 molecules on myeloid cells can be inhibited with two of a panel of 11 monoclonal antibodies (MoAbs) that specifically bind epitopes of human CD13.12 APN has an absolute requirement for zinc for its enzymatic activity, and its extracellular domain includes a pentapeptide sequence (HExxH, at amino acid positions 388 to 392) that mediates zinc binding and catalytic activity in a series of related o 1992 by The American Society of Hematology.
metallopr~teinases.~~ We have now created a deletion mutant of APN that lacks a 39-amino acid segment in the extracellular domain, including the critical pentapeptide motif. Presented here are findings that indicate the location of epitopes that may be important in the zinc-coordinating activities of CD13/APN.
MATERIALS AND METHODS
Construction and expression of a mutant APN cDNA. The full-length human CD13/APN cDNA subcloned in a pBluescript plasmid (Stratagene, La Jolla, CA)' was digested with the BstEII restriction endonuclease, which excised an internal 117-base pair (bp) restriction fragment from the cDNA, but did not cut elsewhere in the cDNA or in the vector. The deleted fragment included the coding sequences for the extracellular zinc-binding motif (HExxH, at amino acid positions 388 to 392; see Fig 1) . The digested cDNA molecules were separated from the small insert fragment by electrophoresis and gel elution, religated, and used to transform XL1 blue bacteria (Stratagene). Digested DNA lacking the deleted sequences was religated correctly to maintain the CD13/APN open-reading frame, as confirmed by sequence analysis using the dideoxynucleotide chain termination method14 as applied to double-stranded DNA templates (Stratagene). Mutant cDNA molecules were excised from the pBluescript plasmid by digestion with Sal1 andXbaI, which cut within the polylinker of the plasmid and in the 3' noncoding sequences of the cDNA, respectively. The insert DNA was recovered by electrophoresis and gel elution and blunt-end-ligated into the unique BamHI site of the retroviral expression vector ~Z I P~~O S V ( X ) -~, '~ provided by Dr Richard A. Mulligan (Whitehead Institute, Boston, MA). Colonies containing recombinant plasmids were identified by hybridization, and a retroviral construct with the mutant CD13/APN cDNA cloned in the correct orientation was isolated and selected on the basis of restriction endonuclease mapping. This construct was transfected into NIH-3T3 cells by calcium phosphate precipitation techniques as previously described.I6 The cells were then cultured in complete medium containing 800 pg/mL G418 (Geneticin; Sigma Chemical, St Louis, MO) to select for transfectants expressing the neomycin resistance gene contained in the vector. Stable G418-resistant transformants were isolated after 2 to 3 weeks.
We had previously generated NIH-3T3 transfectants that expressed high levels of normal human APN,'JZ thus providing a basis for comparison with the deletion mutant. Uchanska-Ziegler, Institut fur Experimentelle Immunologie der Philipps Universitat Marburg, Marburg, Germany.
Cell-surface APN activity was measured with a sensitive spectrophotometric assay, as previously described.12 Briefly, intact NIH/CD13wt cells were incubated at 37°C in isotonic buffer containing 6 mmol/L alanine-p-nitroanilide (Sigma), a substrate for CD13/APN. Samples were periodically Analysis of peptidase activiy.
removed and chilled to arrest enzymatic activity. After centrifugation at PC, cell-free supernatants were assayed for optical density at 405 nm to detect the presence of freep-nitroaniline liberated by cleavage of the substrate by CD13/APN. All measurements were made in triplicate. This assay specifically detects APN activity, as demonstrated by the ability of the aminopeptidase-specific inhibitors bestatin and actinonin to block all catalytic activity.I2 To test for inhibition of cell-surface APN activity by CD13/APN-specific MoAbs, NIH/CD13wt cells were preincubated for 1 hour at 37°C in the presence of saturating concentrations of individual CD13/ APN-specific MoAbs, followed by addition of substrate and measurement of cell-surface APN activity by the above method.
Immunoprecipitation For kinetic studies, parallel cultures of NIH/CD13wt or NIH/ CD13del cells were labeled for 15 minutes with [35S]methionine, followed by incubation in medium containing an excess of cold methionine. At various times of chase, cells were lysed and immunoprecipitated with MoAb MY7, and the immunoprecipitates were analyzed as described above.
RESULTS

Inhibitory
MoAbs do not recognize mutant CD13IAPN molecules. NIH/CD13wt transfectants and NIH/CD13del transfectants were stained with a panel of 19 MoAbs specific for defined extracellular epitopes of CD13/APN, and then were analyzed by flow cytometry. All of the MoAbs recognized epitopes of normal CD13/APN molecules (Fig 2A and C) , whereas four of the 19 (F23, WM15, U71, and U81) did not react with the deletion mutant ( Fig  2F) , suggesting that the epitopes normally recognized by these antibodies were either abolished or modified by the deletion of 39 amino acids from the extracellular domain.
Although 15 of the MoAbs did recognize epitopes on the CD13/APN mutant (Fig 2B and D) , the extent of binding was generally less than one tenth of that with the NIH/ CD13wt transfectants.
Sixteen of the 19 MoAbs, including the four that failed to recognize the deletion mutant, were tested for their ability to inhibit cell-surface A€" activity. A subset of seven MoAbs significantly inhibited the activity of the peptidase, whereas the other nine had little or no effect. The seven inhibitory MoAbs were in two groups: (1) four MoAbs that were highly inhibitory (WM15, F23, U71, and USl), and were the same MoAbs that failed to recognize the mutant CD13/AF"; and (2) three MoAbs with intermediate inhibitory effects (3D8, MY7, and CLB/Mon/Gran/2), which did bind to the CD13/APN mutant (Fig 3) . All nine of the noninhibitory MoAbs recognized epitopes on the CD13/ AI" mutant by flow cytometric assays.
Mutant CDISIAPN molecules lack enzymatic activity. APN activity was measured on the surface of intact parental NIH-3T3 cells, NIH/CD13wt transfectants, and NIH/ CD13del transfectants (Fig 4) . The mutant cells lacked detectable APN activity, indicating that the CD13/APN molecules expressed on their cell surface were enzymatically inactive. NIH/CD13wt cells, by contrast, displayed high levels of APN activity, more than 15 times that of parental NIH-3T3 cells, whose aminopeptidase activity is characteristically 10w.l~ Immunoprecipitated mutant CD13IAPN molecules display alteredprocessing. CD13 /AI" molecules were immunoprecipitated from NIH/CD13wt cells and from NIH/CD13del cells with either MY7 or WM15 MoAbs. The MY7 antibody recognized both normal and mutant CD13/APN molecules in flow cytometric assays (Fig 2) , and immunoprecipitated both normal and mutant molecules (Fig 5, lanes 3 and 6) . By contrast, WM15 recognized normal but not mutant CD13/APN molecules in flow cytometric assays (Fig 2) ; it also immunoprecipitated normal CD13/APN molecules (Fig 5, lane 2) , but not the mutant polypeptides (Fig 5,  lane 5) .
The majority of the normal CD13/APN molecules were present as 150-Kd species, previously shown to be the mature cell-surface form of this enzyme; a minority were present as 130-Kd species, previously shown to be the transient intracellular precursor.lb The CD13/APN deletion mutant also appeared as two species, with electro- (Fig 6, left) , whereas the deletion mutant remained incompletely processed as intracellular precursor molecules even after 8 1 to 3). NIHICD13del cells (lanes 4 to 6) . or parental NIH3T3 cells (lanes 7 to 9). using MoAbs MY7 (lanes 3.6.9). WM15  (lanes 2,5,8), or isotype-matched control myeloma protein (lanes  1.4.7) . Normal CD13/APN molecules were precipitated with either MY7 or WMlS, and were present predominantly as the mature, 150 kD cell surface form (left arrow, lanes 2 and 3) . Mutant CD13/APN molecules were precipitated only by MY7, and were present predominantly as the lower-molecular weight precursor form (right arrow, lane 6).
hours (Fig 6, right) , with only a small percentage of the molecules reaching the cell surface.
DISCUSSION
We have produced a deletion mutant of CD13/APN that lacks a part of the extracellular domain, including a putative zinc-binding motif. Many extracellular epitopes were preserved in the altered CD13/APN molecule, as 15 of 19 CD13/APN-specific MoAbs bound to the mutant glycoproteins. However, the four highly inhibitory MoAbs that failed to bind must recognize epitopes in the vicinity of the critical pentapeptide sequence associated with zinc coordination and catalytic activity. These MoAbs may exert their inhibitory action by interfering with zinc coordination of the native enzyme, by blocking a residue important in catalytic activity, or both. The antigenic determinants of these four MoAbs may also include residues elsewhere on the molecule that would normally be placed in juxtaposition with the deleted amino acids on the normal CD13/APN protein." By contrast, the three MoAbs with intermediate inhibitory effects (3D8, MY7, and CLB/Mon/Gran/2) may recognize epitopes lying near but outside of the deleted segment. Flow cytometric profiles for these three MoAbs were similar to those for the nine noninhibitory MoAbs (Fig  2A-D) , indicating that the epitopes recognized by these MoAbs were fully preserved on the deletion mutant molecules. Steric effects of binding in close proximity to the native enzyme's active site could explain moderate, but incomplete, inhibition of APN activity by this subset of MoAbs.
Comparison of the deleted CD13/APN sequences with sequences of other metalloproteases suggests that they are pivotal in forming a tridentate pocket for zinc in the APN extracellular domain. The pentapeptide sequence containing histidines 388 and 392 (HExxH) is characteristic of zinc-binding metalloproteases.'3.'X Studies of CDlO/neutral endopeptidase have also demonstrated the importance of this extracellular region in enzymatic a~tivity.'~.~" Point mutations of either of the two analogous histidine residues within its similar pentapeptide sequence (HExxH, at amino acid positions 583 to 587) resulted in loss of zinc binding and catalytic activity, whereas a point mutation of a glutamic acid residue contained within the pentapeptide sequence eliminated catalytic activity, apparently without affecting zinc binding.I9 These findings suggest that while zinc coordination is closely associated with the histidine residues present within this critical region, catalytic activity also depends on the presence of other important residues in the enzyme's active site.
Dimerization of APN molecules, which occurs intracellularly during biosynthesis, while the molecules are still in the transient precursor form, may be necessary for the transport of CD13/APN molecules through the Golgi, and is sensitive to even small alterations in molecular structure, as is ultimate processing of the protein to the cell surface.2'.22 In our study, the deletion of a 39-amino acid segment resulted in markedly diminished processing and intracellular retention of mutant CD13/APN molecules, suggesting that the critical dimerization and final processing of these molecules were significantly affected by this deletion. This raises the possibility that levels of normal CD13/APN could be modulated on the surface of a cell by engineering coexpression of mutant CD13/APN, leading to intracellular retention of heterodimers of normal and mutant molecules. Experiments to test this idea are under way.
APN is a widely distributed ectoenzyme found on a spectrum of tissues, including the brush border epithelial cells of small intestine, renal proximal tubules, and placenta. In the small intestine, APN is found on the apical surface of epithelial cells, where it cleaves N-terminal amino acids from small oligopeptides as part of protein d i g e~t i o n .~.~~ This enzyme has also been implicated as having a regulatory role in the inactivation of biologically active oligopeptides, best exemplified by its participation in the degradation of opioid dipeptides on synaptic membranes of the central nervous ~y s t e m .~~-~' The precise function of APN on the surface of myeloid cells is still unknown, although some evidence suggests a regulatory r0le,2~-~* in which the enzyme either removes key residues from active peptides or converts inactive peptides to active forms. The lineage-specific pattern of expression of APN within the hematopoietic system suggests that the enzyme's role may be central to myeloid cell function. Mutational analysis to delineate structural motifs of CD13/APN polypeptides essential for enzymatic activity and binding of inhibitory MoAbs, as described in this report, should prove useful in delineating the role of APN on myeloid cells.
